deltatrials
Completed PHASE3 NCT00092625

Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.

Sponsor: Organon and Co

Conditions Coronary Disease Hypercholesterolemia
Interventions Comparator: ezetimibe, placebo MK0653, ezetimibe
Updated 7 times since 2017 Last updated: Aug 12, 2024 Started: Mar 31, 2003 Primary completion: Jul 31, 2004 Completion: Aug 31, 2004

This PHASE3 trial investigates Coronary Disease and Hypercholesterolemia and is currently completed. Organon and Co leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Organon and Co
Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.